BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million . The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo's net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand for Orladeyo and more pipeline programs advancing into the clinic, starting later this year,” said Jon Stonehouse, president and CEO of BioCryst. In the first quarter, the U.S. commercial team accelerated patients going through annual reimbursement reauthorization from free drug to paid drug faster than in previous years, generating higher than expected Orladeyo revenue. New patient growth remained strong, with the past two quarters having the most new prescriptions in the United States since the first two quarters of the launch. Sales from
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- Fortrea Appoints Machelle Sanders to Board of Directors [Yahoo! Finance]Yahoo! Finance
- BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyGlobeNewswire
- Pint Pharma announces ORLADEYO approval in Mexico for HAE prevention [Yahoo! Finance]Yahoo! Finance
- ORLADEYO® (berotralstat) Approved in MexicoGlobeNewswire
- Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 5/6/24 - Beat
BCRX
Sec Filings
- 5/22/24 - Form 4
- 5/22/24 - Form 4
- 5/15/24 - Form 4
- BCRX's page on the SEC website